As a matter of fact, in a tumor microenvironment congenial condition, obtained through the treatment of lung cancer cells with Transforming Growth Factor-beta (TGF-β) and hypoxia/reoxygenation, there is initial activation and subsequent crosstalk between Epidermal Growth Factor Receptor and NRF2 (174). This evidence concerns the gene NFE2L2 and lung carcinoma.